PURPOSE: MPM is an aggressive malignant tumor of mesothelial origin that shows a limited response to conventional chemotherapy and radiotherapy. Therefore, diagnosing MPM early is very important. ROS play an important role in asbestos toxicity, which is associated with the pathogenesis of MPM development. TRX is a small redox-active protein that demonstrates anti-oxidative activity associated with tumor growth.
METHODS: Here, we investigated the serum levels of TRX in 57 MPM patients and compared them with those of a population that had been exposed to asbestos without developing MPM.
RESULTS: We demonstrated that the patients with MPM had significantly higher serum levels of TRX than the population who had been exposed to asbestos but had not developed MPM Also we demonstrated that the patients with advanced stage MPM showed higher levels of TRX than those with early stage MPM. Since the clinical stage of MPM is not related to the presence or absence of pleural effusion, and the early distinction of MPM patients from those with benign asbestos-related diseases is necessary, we propose that measuring serum TRX levels is an easy and useful method for the clinical management for MPM. Moreover, the difference in overall survival between the groups with serum TRX levels that were lower and higher than the assumed cutoff of 60ng/ml was significant.
CONCLUSIONS: It is suggested that TRX would be a useful serum prognostic factor for MPM.
CLINICAL IMPLICATIONS: This is the first report about the relationship between serum TRX and MPM.
DISCLOSURE: The following authors have nothing to disclose: Risa Maeda, Chiharu Tabata, Rie Tabata, Kazuya Fukuoka, Takashi Nakano
No Product/Research Disclosure Information